The global alopecia market was estimated to be USD 8.78 billion in 2023 and is expected to reach at USD 23.02 billion by 2034 with a CAGR of 9.16% during the forecast period 2024-2034. Growing understanding of available treatments for alopecia, heightened concerns about appearance prompting individuals to actively pursue solutions for hair loss, rising prevalence of hair loss, increasing advancements in alopecia treatment technology, surge in prevalence of chronic diseases linked to hair loss, growing awareness initiatives by diverse organizations, rising demand for pain-free therapies with minimal side effects, and increasing regulatory approvals for innovative alopecia treatments are some of the key factors boosting the market growth.
Increasing regulatory approvals for innovative alopecia treatments is predicted to boost the market growth during the forecast period. Alopecia, commonly referred to as hair loss, is a widespread medical condition characterized by unpredictable hair loss. This autoimmune disorder can lead to partial or complete baldness on the scalp or even across the entire body in severe cases. Topical treatments such as Minoxidil or Rogaine are often prescribed for managing alopecia, alongside other medications occasionally utilized for treating other autoimmune conditions. For instance, in June 2023, Pfizer Inc. has disclosed that LITFULO has received approval from the U.S. FDA, marking the first-ever treatment authorized and utilized for adolescents aged 12 and above for the treatment of severe alopecia areata.
By disease, alopecia areata was the highest revenue-grossing segment in the global alopecia market in 2023 owing to the increase in the occurrence of alopecia areata, heightened patient awareness, surge in the creation of innovative therapies, and positive developments in the approval procedures. For instance, in October 2023, Sun Pharmaceutical Industries Ltd has disclosed that the U.S. FDA has accepted a New Drug Application (NDA) for deuruxolitinib, intended for the treatment of severe alopecia areata. Additionally, alopecia universalis is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness of severe hair loss conditions, surge in research efforts to develop new & efficient treatment choices, and the existence of pipeline medications such as deuruxolitinib, baricitinib, and ritlecitinib for managing severe alopecia areata conditions.
By treatment, pharmaceutical was the highest revenue-grossing segment in the global alopecia market in 2023 owing to the affordability of pharmaceuticals, widespread use of both prescription & over-the-counter medications, growing emphasis on developing innovative drugs for alopecia treatment, and heightened collaboration among industry participants. For instance, in December 2023, Aclaris Therapeutics has unveiled a licensing agreement with Sun Pharmaceutical Industries, Inc., granting Aclaris access to Sun Pharma's JAK inhibitor and various isotopic formulations of ruxolitinib for treating androgenetic alopecia or alopecia areata. Additionally, devices is predicted to grow at the fastest CAGR during the forecast period owing to the rising trend towards the utilization of painless treatments with minimal side effects, increasing preference for laser devices designed for home use, and surge in FDA approval for low-level laser therapy devices targeting the most prevalent types of alopecia, such as androgenetic alopecia.
By gender, male was the highest revenue-grossing segment in the global alopecia market in 2023 owing to the increase in hair loss prevalence among males, rise in tobacco consumption among men, growing elderly population, and an expanding array of clinical trials aimed at developing innovative treatment solutions. For instance, in March 2023, Concert Pharmaceuticals, acquired by Sun Pharmaceutical Industries Limited, has disclosed the results from its Phase 3 clinical trial, THRIVE-AA2. The presentation focuses on the results of the THRIVE-AA2 study, which assessed the effectiveness of the oral investigational drug deuruxolitinib in treating moderate to severe alopecia areata in adult patients. Alopecia areata is an autoimmune condition characterized by patchy or total hair loss on the scalp. Additionally, female is predicted to grow at the fastest CAGR during the forecast period owing to the growing recognition of hair loss issues, shifts in societal expectations, impacts of stress and lifestyle choices, advancements in treatment options, heightened influence of social media, escalating hormonal fluctuations, and a rising emphasis on creating tailored solutions for women's hair loss concerns.
By sales channel, prescription was the highest revenue-grossing segment in the global alopecia market in 2023 owing to the increase in dermatologist visits for hair loss treatment, a robust pipeline of products, rising disposable incomes, an uptick in chronic diseases contributing to hair loss, and an increasing emphasis on developing prescription medications. For instance, in July 2023, REVIAN Inc. has revealed plans for a second study on the Revian Red Hair Growth System, aiming to evaluate its effectiveness as a treatment option for Central Centrifugal Cicatricial Alopecia ("CCCA"). Additionally, OTC is predicted to grow at the fastest CAGR during the forecast period owing to the affordability of treatment and a sizable patient population are key considerations. Over-the-counter (OTC) medications continue to be the top preference for males experiencing androgenetic alopecia and other forms of hair loss conditions lacking approved drugs. This reliance on off-label or OTC medications persists due to the absence of approved options.
By end-user, dermatology clinics was the highest revenue-grossing segment in the global alopecia market in 2023 owing to the increasing use of contemporary treatment approaches such as laser technology, along with a robust lineup of products, and heightened consumer understanding of prescription medications, underscore the trend. Dermatologists, renowned for their capability to offer tailored medications or therapies, are often favored for alopecia treatment due to their ability to deliver effective results. Additionally, homecare setting is predicted to grow at the fastest CAGR during the forecast period owing to the convenience, user-friendliness, and comfort for patients are increasing, as home-use devices receive more regulatory approvals. There's also a rising trend towards non-invasive procedures such as laser therapy, which eliminate the need for lifestyle modifications. For instance, in June 2023, The FDA has granted approval for Yale's alopecia areata treatment, which utilizes ritlecitinib, a Janus kinase (JAK) inhibitor suitable for adolescents and adults suffering from the condition.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising consumer awareness, healthcare infrastructure has improved, surge in technological advancements, growing adoption of laser-based therapy for treatment, and growing trend of mergers and acquisitions among industry players. For instance, in January 2023, Sun Pharmaceuticals Industries Ltd revealed its acquisition of Concert Pharmaceuticals, a biotechnology firm specializing in the treatment of alopecia areata. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing occurrence of alopecia, a heightened demand for efficient treatment solutions, rising awareness regarding hair loss & its implications on quality of life, growing disposable incomes & lifestyle changes, and growing number of clinical trials. For instance, in August 2023, Kintor Pharmaceutical Limited has announced the conclusion of the enrollment phase for the phase II clinical trial of KX-826 in China, intended for the treatment of male androgenetic alopecia.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Increasing regulatory approvals for innovative alopecia treatments is predicted to boost the market growth during the forecast period. Alopecia, commonly referred to as hair loss, is a widespread medical condition characterized by unpredictable hair loss. This autoimmune disorder can lead to partial or complete baldness on the scalp or even across the entire body in severe cases. Topical treatments such as Minoxidil or Rogaine are often prescribed for managing alopecia, alongside other medications occasionally utilized for treating other autoimmune conditions. For instance, in June 2023, Pfizer Inc. has disclosed that LITFULO has received approval from the U.S. FDA, marking the first-ever treatment authorized and utilized for adolescents aged 12 and above for the treatment of severe alopecia areata.
By disease, alopecia areata was the highest revenue-grossing segment in the global alopecia market in 2023 owing to the increase in the occurrence of alopecia areata, heightened patient awareness, surge in the creation of innovative therapies, and positive developments in the approval procedures. For instance, in October 2023, Sun Pharmaceutical Industries Ltd has disclosed that the U.S. FDA has accepted a New Drug Application (NDA) for deuruxolitinib, intended for the treatment of severe alopecia areata. Additionally, alopecia universalis is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness of severe hair loss conditions, surge in research efforts to develop new & efficient treatment choices, and the existence of pipeline medications such as deuruxolitinib, baricitinib, and ritlecitinib for managing severe alopecia areata conditions.
By treatment, pharmaceutical was the highest revenue-grossing segment in the global alopecia market in 2023 owing to the affordability of pharmaceuticals, widespread use of both prescription & over-the-counter medications, growing emphasis on developing innovative drugs for alopecia treatment, and heightened collaboration among industry participants. For instance, in December 2023, Aclaris Therapeutics has unveiled a licensing agreement with Sun Pharmaceutical Industries, Inc., granting Aclaris access to Sun Pharma's JAK inhibitor and various isotopic formulations of ruxolitinib for treating androgenetic alopecia or alopecia areata. Additionally, devices is predicted to grow at the fastest CAGR during the forecast period owing to the rising trend towards the utilization of painless treatments with minimal side effects, increasing preference for laser devices designed for home use, and surge in FDA approval for low-level laser therapy devices targeting the most prevalent types of alopecia, such as androgenetic alopecia.
By gender, male was the highest revenue-grossing segment in the global alopecia market in 2023 owing to the increase in hair loss prevalence among males, rise in tobacco consumption among men, growing elderly population, and an expanding array of clinical trials aimed at developing innovative treatment solutions. For instance, in March 2023, Concert Pharmaceuticals, acquired by Sun Pharmaceutical Industries Limited, has disclosed the results from its Phase 3 clinical trial, THRIVE-AA2. The presentation focuses on the results of the THRIVE-AA2 study, which assessed the effectiveness of the oral investigational drug deuruxolitinib in treating moderate to severe alopecia areata in adult patients. Alopecia areata is an autoimmune condition characterized by patchy or total hair loss on the scalp. Additionally, female is predicted to grow at the fastest CAGR during the forecast period owing to the growing recognition of hair loss issues, shifts in societal expectations, impacts of stress and lifestyle choices, advancements in treatment options, heightened influence of social media, escalating hormonal fluctuations, and a rising emphasis on creating tailored solutions for women's hair loss concerns.
By sales channel, prescription was the highest revenue-grossing segment in the global alopecia market in 2023 owing to the increase in dermatologist visits for hair loss treatment, a robust pipeline of products, rising disposable incomes, an uptick in chronic diseases contributing to hair loss, and an increasing emphasis on developing prescription medications. For instance, in July 2023, REVIAN Inc. has revealed plans for a second study on the Revian Red Hair Growth System, aiming to evaluate its effectiveness as a treatment option for Central Centrifugal Cicatricial Alopecia ("CCCA"). Additionally, OTC is predicted to grow at the fastest CAGR during the forecast period owing to the affordability of treatment and a sizable patient population are key considerations. Over-the-counter (OTC) medications continue to be the top preference for males experiencing androgenetic alopecia and other forms of hair loss conditions lacking approved drugs. This reliance on off-label or OTC medications persists due to the absence of approved options.
By end-user, dermatology clinics was the highest revenue-grossing segment in the global alopecia market in 2023 owing to the increasing use of contemporary treatment approaches such as laser technology, along with a robust lineup of products, and heightened consumer understanding of prescription medications, underscore the trend. Dermatologists, renowned for their capability to offer tailored medications or therapies, are often favored for alopecia treatment due to their ability to deliver effective results. Additionally, homecare setting is predicted to grow at the fastest CAGR during the forecast period owing to the convenience, user-friendliness, and comfort for patients are increasing, as home-use devices receive more regulatory approvals. There's also a rising trend towards non-invasive procedures such as laser therapy, which eliminate the need for lifestyle modifications. For instance, in June 2023, The FDA has granted approval for Yale's alopecia areata treatment, which utilizes ritlecitinib, a Janus kinase (JAK) inhibitor suitable for adolescents and adults suffering from the condition.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising consumer awareness, healthcare infrastructure has improved, surge in technological advancements, growing adoption of laser-based therapy for treatment, and growing trend of mergers and acquisitions among industry players. For instance, in January 2023, Sun Pharmaceuticals Industries Ltd revealed its acquisition of Concert Pharmaceuticals, a biotechnology firm specializing in the treatment of alopecia areata. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing occurrence of alopecia, a heightened demand for efficient treatment solutions, rising awareness regarding hair loss & its implications on quality of life, growing disposable incomes & lifestyle changes, and growing number of clinical trials. For instance, in August 2023, Kintor Pharmaceutical Limited has announced the conclusion of the enrollment phase for the phase II clinical trial of KX-826 in China, intended for the treatment of male androgenetic alopecia.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Disease, Treatment, Gender, Sales Channel, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
Segmentation: Alopecia Market Report 2023 - 2034
Alopecia Market Analysis & Forecast by Disease 2023 - 2034 (Revenue USD Bn)
- Androgenetic Alopecia
- Alopecia Universalis
- Cicatricial Alopecia
- Traction Alopecia
- Alopecia Totalis
- Alopecia Areata
- Others
Alopecia Market Analysis & Forecast by Treatment 2023 - 2034 (Revenue USD Bn)
- Devices
- Laser Helmet
- Laser Comb
- Laser Cap
- Pharmaceuticals
- PRP
- Oral
- OTC
- Corticosteroids
- Prescription
- Finasteride
- Minoxidil
- Others (JAK Inhibitors & 0thers))
- Topical
- OTC
- Minoxidil
- Others
- Prescription
- Minoxidil
- Finasteride
- Fluocinolone Acetonide
- Betamethasone Dipropionate
Alopecia Market Analysis & Forecast by Gender 2023 - 2034 (Revenue USD Bn)
- Female
- Male
Alopecia Market Analysis & Forecast by Sales Channel 2023 - 2034 (Revenue USD Bn)
- OTC
- Prescriptions
Alopecia Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Dermatology Clinics
- Homecare Settings
Alopecia Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Alopecia Market: Disease Estimates & Trend Analysis
8. Alopecia Market: Treatment Estimates & Trend Analysis
9. Alopecia Market: Gender Estimates & Trend Analysis
10. Alopecia Market: Sales Channel Estimates & Trend Analysis
11. Alopecia Market: End-user Estimates & Trend Analysis
12. Regional Market Analysis
13. North America Alopecia Market
14. Europe Global Alopecia Market
15. Asia Pacific Global Alopecia Market
16. Latin America Global Alopecia Market
17. MEA Global Alopecia Market
18. Competitor Analysis
19. Company Profiles
Companies Mentioned
- Cipla Limited
- Merck & Co. Inc.
- Viatris Inc.
- Pfizer Inc.
- GlaxoSmithKline plc
- Aurobindo Pharma
- Janssen Global Services Inc.
- Theradome
- Lilly
- Sun Pharmaceuticals Industries Ltd
- Lutronic
- Lexington Intl. LLC (Devices)
- Dr. Reddy’s Laboratories Ltd
- Curallux LLC.
- Apira Science Inc. (iGROW Laser)
- Freedom Laser Therapy (iRestore ID-520 helmet)
- Revian Inc.
